Physician profile
Jayson Jun
NPI 1760808240
$16,626.12
in general payments reported to CMS, 2019-2025
25 companies · $5,161 in 2025
The $5,161 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,026 · 2022: $2,396 · 2023: $2,619 · 2024: $4,424 · 2025: $5,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $17.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,186.00 |
| Education | $17.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,069.55 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,962.58 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,601.83 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,551.62 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,408.42 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,219.09 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $1,069.20 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,044.52 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $976.83 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $575.57 | 2022-2025 | Auvelity |
| Noven Therapeutics, LLC | $508.86 | 2021-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $446.46 | 2021-2025 | Trintellix |
| Indivior INC. | $420.88 | 2022-2025 | Sublocade, Perseris |
| Corium, LLC | $377.61 | 2021-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $303.35 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $231.16 | 2022-2024 | Loreev Xr, Sertraline Hcl, Citalopram |
| Ironshore Pharmaceuticals INC. | $179.08 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $167.05 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $164.36 | 2022-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $142.23 | 2023-2025 | Quviviq, Quviviq |
| Bausch Health US, LLC | $94.77 | 2023-2024 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $36.74 | 2025 | Adzenys Xr-Odt |
| Avadel Cns Pharmaceuticals, LLC | $31.97 | 2025 | Lumryz |
| Brainsway USA INC | $25.76 | 2023-2025 | Deep Tms System |
| Tris Pharma INC | $16.63 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Jun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.